Royal Bank of Canada
INDV icon

Royal Bank of Canada’s Indivior Pharmaceuticals INDV Stock Holding History

Royal Bank of Canada’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$925K Sell
30,332
-1,822
-6% -$60.2K ﹤0.01% 3684
2025
Q4 		$1.15M Sell
32,154
-70,470
-69% -$2.15M ﹤0.01% 3566
2025
Q3 		$2.48M Buy
102,624
+74,418
+264% +$1.56M ﹤0.01% 3215
2025
Q2 		$416K Sell
28,206
-436
-2% -$5.08K ﹤0.01% 4609
2025
Q1 		$273K Sell
28,642
-519
-2% -$5.46K ﹤0.01% 4472
2024
Q4 		$362K Sell
29,161
-1,160
-4% -$11.9K ﹤0.01% 4334
2024
Q3 		$295K Sell
30,321
-2,298
-7% -$26.9K ﹤0.01% 4518
2024
Q2 		$525K Sell
32,619
-9,769
-23% -$176K ﹤0.01% 3980
2024
Q1 		$908K Buy
42,388
+763
+2% +$14.3K ﹤0.01% 3543
2023
Q4 		$636K Buy
41,625
+3,970
+11% +$70.5K ﹤0.01% 4054
2023
Q3 		$869K Sell
37,655
-790
-2% -$18K ﹤0.01% 3549
2023
Q2 		$915K Buy
+38,445
New +$881K ﹤0.01% 3437

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada's INDV Position: Q1 2026 in Review

Royal Bank of Canada reduced its Indivior Pharmaceuticals (INDV) stake by 5.7% in Q1 2026, selling an estimated $60.2K and leaving 30,332 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #3684.

Royal Bank of Canada first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $2.48M in Q3 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Royal Bank of Canada held 30,332 shares of Indivior Pharmaceuticals worth $925K as of Q1 2026.
  • Royal Bank of Canada sold 1,822 Indivior Pharmaceuticals shares in Q1 2026, an estimated $60.2K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3684 holding.
  • Royal Bank of Canada first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Royal Bank of Canada's Indivior Pharmaceuticals position peaked at $2.48M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.